SEC charges Texas investor with insider trading after Cancer Genetics’ 2020 mergernews2025-08-12T15:55:37+00:00August 12th, 2025|Endpoints News|
PureTech spins out its IPF drug as it readies for Phase 3 meeting with the FDAnews2025-08-12T15:36:17+00:00August 12th, 2025|Endpoints News|
Sarepta details Elevidys’ liver toxicity data and plans for safety studynews2025-08-12T15:25:39+00:00August 12th, 2025|Endpoints News|
ICHRA collides with an increasingly unstable individual marketnews2025-08-12T15:15:33+00:00August 12th, 2025|Endpoints News|
Sanofi, Regeneron’s cholesterol drug is in short supply in Chinanews2025-08-12T14:04:43+00:00August 12th, 2025|Endpoints News|
Biohaven scraps Phase 3 OCD program; Fosun’s licensing deal with Expedition news2025-08-12T13:57:47+00:00August 12th, 2025|Endpoints News|
Doximity buys Pathway for $63M in AI pushnews2025-08-12T13:55:06+00:00August 12th, 2025|Endpoints News|
The future of ICHRA hinges on a market in meltdownnews2025-08-12T13:00:46+00:00August 12th, 2025|Endpoints News|
Endpoints livestream: What RFK’s exile of mRNA says about MAHA and biotechnews2025-08-12T12:00:25+00:00August 12th, 2025|Endpoints News|
Novartis’ antibody ianalumab clinches another Phase 3 win, this time in a rare blood diseasenews2025-08-12T11:12:37+00:00August 12th, 2025|Endpoints News|
